INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us

Setting Your Sites on Successful Clinical Trials

Anne Marie Gaulin

Anne Marie Gaulin

Executive VP, International Expansion

Author picture

 

In the article “Setting Your Sites on Successful Clinical Trials,” Anne Marie Gaulin, Executive VP of International Expansion at Indero, discusses:

  • The pivotal role of investigative sites in clinical trials. Gaulin emphasizes that the selection of sites and nurturing long-standing partnerships with them are crucial for the success of clinical trials.
  • The article explores how specialist CROs can invest time and resources into building strong site relationships to benefit trial sponsors.
  • It covers challenges such as patient recruitment, retention, regulatory compliance, and data integrity, highlighting the significant influence of research sites on study timelines and drug approval.

For a detailed exploration of these topics and more, read the full article here:

  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.
Talk to us

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte prĂšs de 30 ans d’expĂ©rience dans l’industrie pharmaceutique et CRO, s’Ă©tant distinguĂ© par son leadership exceptionnel, sa vision stratĂ©gique et son innovation. L’expertise de Jeff couvre des opĂ©rations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matiĂšre de crĂ©ation de valeur, de gestion des partenaires et d’opĂ©rations CRO ont toujours contribuĂ© au succĂšs dans ses fonctions prĂ©cĂ©dentes. Sous la direction de Jeff, Indero continue d’étendre ses capacitĂ©s, faisant progresser les connaissances mĂ©dicales et les nouvelles thĂ©rapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≀3 days, and lowers costs, helping teams make informed go/no-go decisions faster.
LEARN MORE >